Microcap & Penny StocksPEN Inc

Previous 10 Next 10 
To: Ron Dior who wrote (32)12/2/2011 12:45:18 PM
From: donpat
   of 176
I was IN the patent biz for 35 years and can't get it out of my system! One of these days!!!

I like nanotech's prospects be it in materials strengthening or medicine delivery, diagnosis and treatment - and ANI is involved in all of those.

So I follow it, having bought in over the years - averaging out at ~ 90¢.

It's a pastime!

I leave my real money with pros!

I'm now in the position of wanting/needing to be vindicated.

We shall see, soon, I hope!

Share RecommendKeepReplyMark as Last Read

From: donpat12/4/2011 12:04:38 PM
1 Recommendation   of 176
Apple’s 2012 i HDTV- Filling In The Blanks

[My note: RAMAN rules!]

July 5th, 2011 ·

4 Comments · 3D HDTV, CNT FED, Connected TVs, LCD Flat Panel, LED LCD Flat Panels, News

A number of websites have leaked information about an upcoming Apple iHDTV. HD Guru examined the bits and pieces, and together with information on new technologies from other HDTV tech stories and the recent SID show, we’ve put together a picture of what we expect from Apple as the next HDTV maker.


With Apple’s long tradition breaking new ground, we anticipate the Apple iHDTV to launch with significant HDTV improvements.

It’s a given the iHDTV will have the Apple iOS found in the Apple TV box, iPhone and iPad. In addition, it’s a safe bet to assume Apple’s upcoming iCloud system will be included as well, with movies and TV programs.


There’s a long relationship between Samsung and Apple for components. This, coupled with Samsung’s LCD manufacturing partnership with Sony and other TV makers, other websites are predicting Samsung as the panel supplier and we concur.

It’s possible, though, that this Apple/Samsung TV will feature a next-generation display technology that will outperform today’s cutting-edge LED LCDs.

According to a number of reports out of Asia including the etnews, late last year Samsung began the conversion of one of its plasma plants to produce Carbon Nano Tube Field Emitter Display (CNT-FED) Back Light Units. A CNT-FED would replace LEDs to create the light for LCDs. One of the main advantages of this technology is the ability to provide very local dimming. Single-pixel local dimming is possible, if the design/cost calls for it.. The result is totally black pixels next to brightly lit pixels (insanely high legitimate contrast ratios), plus lower power consumption.

Here is how they work as explained by Jim Kim’s website in 2008. “Field emission technology is a variation on how CRTs and plasmas work by using electrons to excite phosphors on a screen. In Samsung's example, the control is fine tuned by the use of carbon nanotubes and a unique structure. The carbon nanotubes are used as emissive tips. Nanotubes are deposited on a flat surface and is treated with an elastomer. The elastomer allows the exposed nanotubes to stand up, which then can be used as emissive tips. A TFT-like grid is layered above the nanotubes to control the movement of electrons to excite the red, green and blue phosphors.”

According to ET news, the first CNT-FED backlight units will be 46-Inch screen size, an ideal size for Apple and the size of Samsung’s current best selling model.

Further improving performance would be the use of Samsung’s new VA 1 (Vertical Alignment) display with its wider viewing angle and faster refresh ( link).

We expect this iHDTV to launch by end of Q1 2012. The price? Well, it’s Apple, so probably not cheap, but not too expensive either.

Share RecommendKeepReplyMark as Last ReadRead Replies (1)

To: donpat who wrote (34)12/4/2011 8:37:12 PM
From: donpat
   of 176
Switched On: Keeping the 'app' out of Apple's TV

By Ross Rubin posted Dec 4th 2011 8:24PM

Each week Ross Rubin contributes Switched On, a column about consumer technology.

Rumors continue to heat up that Apple will enter the television market next year, stepping up its Apple TV "hobby" into a greater revenue-generating vocation. The company would clearly like to repeat the kind of rousing success it has seen in smartphones. There, it entered a market at least as crowded and competitive as that for televisions whereas most of its Windows rivals have barely been able to eke out a few models with nominal share..

Indeed, the challenge is not as much about competition as commoditization. At first glance, this would be a curious time for Apple to enter the TV space. The HD and flat-panel transitions on which premium manufacturer brands and retailers once feasted has long passed. "Flat-panel TV" and "HDTV" are now just "TV." And prices for smaller sets are settling into a range familiar to those who remember what they cost back in the heyday of CRTs.

What's different, though, is that the state of the smart TV market looks strikingly like the smartphone market did before Apple's entrance. The market essentially has "feature TVs" that present a few popular canned services (YouTube, Netflix, Hulu, Pandora, etc.) and "smart TVs" that are a fractured mixture of homegrown offerings (from companies such as Panasonic, Samsung, LG and Toshiba) and an experience-challenged licensed OS (Android from Sony and Vizio).
The company has clung to the idea of TV as a passive experience.This doesn't mean, though, that Apple would necessarily see its television as a way to extend the iOS developer base any more than it has opened up the Mac to such apps, at least at launch. Switched On has previously discussed the challenges that TV-based apps face. If putting such apps on a TV was Apple's plan, why wouldn't it get it started via support on today's Apple TV box? Even if Apple exceeds its wildest dreams for success with an Apple-branded television, there will be a much, much larger base of Apple TV-accessible HDTVs from other brands available for the foreseeable future.

The company has clung to the idea of TV as a passive experience. Indeed, enabling iPhone-like apps on a TV would likely require some Magic Trackpad-like remote, which is not, in the words of Steve Jobs, "the simplest user interface you could imagine." So, what is Apple's opportunity then? There are at least two paths it can take to creating a compelling, differentiated TV experience. They are:

Aggregation: Switched On has also previously discussed the promise of an iTunes-based subscription alternative to cable. Alas, it has been difficult for any company to coax content owners to abandon their lucrative cable compensation deals. And while Apple may have the cash to do so, it doesn't seem like the sort of spendy deal in Apple's character. Of course, user interface and input would play a huge role. Siri or some Siri-like agent could pluck shows from across services such as Netflix and Hulu if Apple can't pull together an integrated subscription service of its own and repeat the disruption it originally made with the iTunes Music Store..

Integration: The cliche "if you can't beat 'em, join 'em" hasn't worked in the world of broadband television. As difficult as it has been to assemble a competitive show lineup to facilities-based incumbent TV service providers, it hasn't been much easier to integrate the richness of that platform. Most have tried either the kludgey (IR emitters used by early TiVo boxes and the Logitech Revue) to the obscure (CableCARD, used by modern TiV0 boxes, which is hardly universal in the U.S. much lsess Apple's other global markets).

If Apple were to find some way to remix the content that most consumers were already paying for, it would have a huge advantage versus other TV makers. But Comcast and TimeWarner have been slow to provide the keys to the content kingdom to even current high-volume TV companies such as Samsung and Sony. Historically, Apple has been one ring away from Netflix on cable company dartboards, although many of them can't seem to rush enough video to the iPad today. Perhaps Apple could use the iPad as a leverage point. After all, a simple cable or AirPlay support is all that separates its display form a television today.

Over the next few years, Internet connectivity will become a common feature in TV sets. It is already becoming so in 40-inch+ models. Apple seems to be under no pressure to enter the market. With its current Apple TV,it can send a wide range video content up to a television with ease, and future versions of Wi-Fi will easily support the ability to do so in the best quality available. It's almost certain that an Apple-branded television would (and would have to) differentiate on user experience well beyond an engagement level that Apple TV delivers today. Beyond that, optimizing the selection and presentation of the content consumers want is the critical task for any company that would seek to reinvent the TV.

Share RecommendKeepReplyMark as Last Read

To: donpat who wrote (30)12/5/2011 5:29:04 PM
From: donpat
1 Recommendation   of 176
More on EZKnowz™
Transition from Venture Formation to

Dr. Royce Johnson

Dr. Royce Johnson has driven innovation, patented advancements, and life-saving solutions in biomedical technology for three decades, with an emphasis on clinical systems and critical care physiology. After a 30-year career of instigating medical technology innovation from within industry, Dr. Johnson is now applying his skills and creativity to a broader range of clients.

The focus of his work has evolved from early-stage technology incubation to addressing the front end of innovation with a deep understanding of the customer. As he says, “the technology is the easy part". Trained in biomedical engineering, technology management, and strategic innovation, he is an expert in devising novel solutions to unrecognized opportunities across the clinical workplace domain.

During his 14-year tenure with therapeutic medical device developer KCI, Dr. Johnson advanced through roles as principal scientist, manager/director of new technologies, director of innovation and ideation, and corporate fellow for research. He was the first- or co-inventor of 17 issued U.S. patents, including breakthrough developments revolutionizing wound therapy, tissue engineering, skin grafting, phototherapy, and therapeutic hypothermia [ ].

While with KCI, Dr. Johnson also led the creation and implementation of the entire front end of their commercialization processes, from technology strategy to opportunity portfolio management. These processes were built in part on the “outside-in perspectives derived from his ethnographic demand studies and they continue to generate numerous innovations for the firm. Doing more than studies, he ultimately brought the outside-in home: he championed, designed, implemented, and directed the company's acclaimed internal clinical simulation suite (complete with an OR, ICU, conference center, and support spaces) as a core resource for in-context, hands-on education of both clinical customers and the product commercialization teams.

Prior to joining KCI, Dr. Johnson spent his early career with Ohmeda, Inc. (now GE Healthcare) and Baxter Healthcare as a project engineer and manager of advanced development/applied technologies.

Recognized twice by Frost & Sullivan as their “Most Valuable Thought Leader in MindXchange Programs, Dr. Johnson teaches these skills in independent workshops and in his role as adjunct professor at Texas universities. Currently conducting research in nursing care process quality technology, he has published in fields as diverse as critical care physiology and strategic opportunity assessment.

Dr. Johnson earned his bachelor's, master's, and doctoral degrees in biology and bioengineering at the University of Utah and holds a certificate in strategy and innovation from MIT Sloan School of Management. Now independently practicing in strategic innovation, Dr. Johnson continues to pursue his professional goal of applying and teaching the skills that enable large companies to innovate effectively.

Web: n LinkedIn:

See slide 38 here:

I assume he is advising ANI on EZKnowz™ et al.

Share RecommendKeepReplyMark as Last ReadRead Replies (1)

From: donpat12/7/2011 11:45:14 AM
   of 176
Applied Nanotech Awarded Patent for EZKnowz(TM), a Multiple-Gas Breath Sensor for the Detection of Potential Disease States

Appoints Dr. Royce Johnson to Accelerate Business Development in Medical Sectors

AUSTIN, Texas, Dec. 7, 2011 (GLOBE NEWSWIRE) -- Applied Nanotech Holdings, Inc. (OTCBB:APNT.OB - News) is pleased to announce that it has been awarded European Patent EP1976431B1 [ ], for its EZKnowz(TM), a multiple-gas breath sensor for use in medical applications for the detection of potential disease states. This patent covers the complete EZKnowz(TM) sensor platform, including a sample collector, analysis device and data storage device.

The EZKnowz(TM) sensor platform, developed by Applied Nanotech, combines existing differential ion mobility spectrometry technology with Applied Nanotech's proprietary non-radioactive ion source. The EZKnowz(TM) sensor platform is capable of sensing a broad range of gas species and selecting specific gasses in a complex environment. The levels of detection of the EZKnowz(TM) sensor platform for many gasses are on the range of parts per billion (one or more molecules in a concentration of one billion other gas molecules) and in some cases, in the range of parts per trillion, sufficient for many applications.

Unlike other breath detection systems on the market that are limited to centralized laboratories or facilities because of their size, EZKnowz(TM) is a compact, portable system that can be used in a variety of settings, including laboratories, doctor's offices and home-health environments. EZKnowz(TM) has the potential to detect a variety gases and diseases, including Mercaptan/BTEX, lung cancer detection, influenza detection, pharmaceutical contamination, wound healing/infection detection and plant disease detection. In addition, EZKnowz(TM) has been shown to identify body odor biometrics for use in military and homeland security applications, including the detection of explosives.

Applied Nanotech is also pleased to announce that it has hired Dr. Royce Johnson to accelerate its business development initiatives in medical sectors. Dr. Johnson spent 14 years with therapeutic medical device developer, Kinetic Concepts, Inc. (KCI), where he was instrumental in developing and commercializing breakthrough developments revolutionizing wound therapy, tissue engineering, skin grafting, phototherapy, and therapeutic hypothermia. Dr. Johnson was twice recognized by Frost & Sullivan as their Most Valuable Thought Leader in MindXchange Programs. He earned his bachelor's, master's, and doctoral degrees in biology and bioengineering at the University of Utah and holds a certificate in strategy and innovation from MIT Sloan School of Management.

Share RecommendKeepReplyMark as Last Read

From: donpat12/9/2011 11:07:47 AM
   of 176
Nano-technology can put an end to our current woes: CNR Rao

Published: Friday, Dec 9, 2011, 15:18 IST

By DNA Correspondent | Place: Bangalore | Agency: DNA

Addressing a packed gathering of students and academicians at the fourth Bangalore Nano, Scientist and chairman of the prime minister’s science advisory council, Professor CNR Rao, said nano-technology would be the answer to the world’s energy crisis.

“India currently uses 3.5lakh MW to 4 lakh MW of power and in a matter of time, it will reach 8 lakh MW. This will be a burning problem,” he said, adding that nuclear technology would not be able to meet the demand.

“There are those who say that nuclear technology can generate up to 2 lakh MW of power. But here’s the thing; all the available uranium in the world won’t be able to generate that much!” he quipped. Rao elucidated that water and nanotechnology would be major players in deterring the energy crisis. “Water is the future coal of mankind. We need to split water into hydrogen,” he explained.

Rao also elaborated on the various fields that will benefit from nano-technology. “Some of the applications of nano-technology are nano-lithography, nano-electronics, field emission and more,” he added.

While he focused on the future, Rao paid tribute to the past as well, saying that humans have been putting nanotechnology to use for centuries. “The Damascus sword (a sword used in West Asia in the 17th century) actually contains carbon nanotubes, making it stronger,” he said, adding that the Raman Spectroscopy (observed first by CV Raman) is used as an important tool in this field.

Share RecommendKeepReplyMark as Last Read

From: donpat12/12/2011 11:52:07 AM
   of 176
Medicine Needs Frugal Innovation

A low-cost pocket ultrasound device can see into the human heart. So why do so few doctors use it?

Inside track: Cardiologist Eric Topol demonstrates a portable ultrasound device made by GE, the Vscan. It uses sound waves to create images of internal organs.


In the history of medical innovation, advances in technology have been inextricably linked to increases in cost. But we are at a unique moment in which the insular world of medicine is about to be penetrated by the remarkable digital infrastructure. Think about the cost of computing. Over the past two decades, cost has been relentlessly reduced while capacity and performance have dramatically increased. How and when can this trend reach the practice of medicine, where costs often go up with little real improvement?

Let's consider the icon of medicine—the stethoscope draped around the doctor's neck or in the pocket of a white coat. Invented by René Laënnec in 1816, the stethoscope didn't see routine use by the medical community for another 20 years. The lag in acceptance reflected the conservative nature of physicians, who objected to having to learn heart sounds and let an instrument get between their healing hands and the patient.

Now, nearly 200 years later, economic forces are greatly slowing the adoption of a powerful replacement for the stethoscope in cardiac medicine. Instead of listening to the heart of a patient, I can now watch it on a device no bigger than a cell phone—a high-resolution miniature ultrasound probe. In fact, in my clinic I have not used a stethoscope to examine a patient's heart for the past two years.

Why would I listen to the "lub-dub" of heart sounds when I can actually see everything relevant about the heart in real time? Exquisite ultrasound images of the heart muscle—showing its contraction, its thickness, the size of the chambers, the valves, the sac around the heart—can all be obtained within seconds as part of a routine physical examination. I can share and discuss the images with the patient as they are being acquired, put video recordings in the electronic medical record, and send them to the patient or referring physician. The up-front cost of the pocket ultrasound device is about $7,700, but there is no extra cost for an unlimited number of readings.

That makes these small devices a formidable challenge to business as usual in American health care. Each year in the United States more than 20 million echocardiograms (ultrasounds of the heart) are performed, and so are a similar number of abdominal and fetal ultrasound examinations. Each of these diagnostic procedures is done in a dedicated laboratory setting, either in the hospital or in a doctor's office, with expensive equipment—and a combined professional and technical charge of $1,000 to $2,000. The math is straightforward. If a pocket ultrasound device were incorporated into routine physical exams the same way we use a stethoscope, several billion dollars in unnecessary charges would be saved each year.

Therein lies the rub—and the explanation for why many low-cost innovations are being held back in medicine. Those savings would represent a critical hit to revenue for doctors and hospitals. It's not just that doctors, like those who refused to use the stethoscope, are intrinsically conservative. The American health-care model of billing "medicine by the yard" creates economic disincentives to cost-saving technology. In contrast, pocket high-resolution ultrasound has been rapidly adopted and hailed as a breakthrough in countries such as India, China, and Brazil.

This represents just a single, simple example of how frugal innovation—the idea of coupling engineering creativity with lower costs—could be achieved if patient care in the United States were not determined by reimbursement rules. We now have wireless sensors that can help us diagnose sleep apnea by capturing all the relevant data for sleep studies—respiratory rate, oxygen saturation of the blood. The data can easily be captured for less than $100, right in a patient's home. But instead, the medical community keeps using $3,000-per-night hospital sleep labs to make the diagnosis.

I believe a great inflection is coming in medicine: advances in technology will finally help us override the reimbursement issue and topple the economic models that physicians, insurers, and hospitals still cling to. This moment will arrive as medicine is opened to the digital infrastructure of mobile wireless devices, pervasive connectivity, ever-expanding bandwidth, cloud and supercomputing power, and the Internet. Superimposed on these digital capabilities are the ones specific to health care—genomic sequencing, biosensors, advanced imaging, and health information systems. It will all lead to what I call "high-definition man": a panoramic, granular profile of an individual's molecular biology, physiology, and anatomy.

Medicine, in short, has the potential for better technology at a much lower price, but don't look to the medical profession, government, or the life-sciences industry to make the change on its own. I believe the change will come when consumers demand it. The Arab Spring and the Occupy Wall Street movement have shown the influence of social networks as a way to express citizens' demands. Don't be surprised if health care is occupied next.

Eric J. Topol is chief academic officer of Scripps Health, director of the Scripps Translational Science Institute, professor of genomics at the Scripps Research Institute, and a cardiologist at Scripps Clinic. He is the author of The Creative Destruction of Medicine: How the Digital Revolution Will Create Better Health Care.

Share RecommendKeepReplyMark as Last Read

From: donpat12/13/2011 9:13:02 PM
   of 176
Strong Nano Tech Wood Nears Production

By Bill Esler | 12/13/2011 12:03:00 PM

MONTREAL - Nano technology will soon enter the wood products lexicon, as CelluForce starts up its first plant. Super wood products spun from NanoCrystallin Cellulose (NCC), could include jumbo jets, bridges as well as fabrics and electronics.

CelluForce was formed as a joint venture by forestry and paper firm Domtar Corp. and FPInnovations. For the last eight weeks, CelluForce has been progressively starting up the equipment for the first ever large-scale production of NCC.

Nanomaterials consist of particles or fibers smaller in dimension than the width of a human hair, which combine to form extremely strong yet lightweight materials.

The first CelluForce products, which go under the brand names of CelluForce Impact and CelluForce Allure, will be produced in state-of-the-art facilities located at Domtar's pulp and paper plant in Windsor, Quebec. Construction extended over a fourteen-month period. It required a total investment of $36M including the financial participation of both the Federal and Québec governments.

NanoCrystalline Cellulose is composed of crystallites with average dimensions of 100nm length and 5nm diameter.

"Wood pulp is being delivered to the plant to test the new equipment and we are making progress on a daily basis," says CEO Jean Moreau. While furniture and particleboard are not on the dawing boards, Moreau says nano-based materials could find their way into many markets.

Montreal-based CelluForce has a workforce of 30 employees operating the first manufacturing plant for NanoCrystalline Cellulose in the world. The 25 involved in production and development since June 2011 went through intensive training sessions, says Rene Goguen, VP manufacturing, "to ensure they were ready to start up the specialized equipment, most of which was custom-built."

Trials integrating NanoCrystalline Cellulose into the manufacturing process of different products are currently taking place, says Moreau, who says he expects to sign initial contracts soon.

Recyclable and renewable, the cellulose derived nano materials improve strength, durability and toughness, and can reduce damage caused by wear, abrasion and light. It can be incorporated into systems to make structures that are light reflective (tunable from ultraviolet to infrared), impermeable to gas and stable over time. Moreau says the advanced material derived from wood fiber will lead to commercial applications largely exceeding those of traditional wood fibre products.

14 results found in the Worldwide database for:
NANOCRYSTALLINE CELLULOSE in the title or abstract AND FPInnovations as the applicant


NCC forms stable suspensions
NCC can be dried and resuspended with full recovery of properties
NCC self-assembles into suprastructures that have low porosity and unique optical properties.
NCC forms stable suspensions that self-assemble into oriented films upon drying.

For more on this, see Beck, S., Bouchard
NCC in a fluid form can be oriented through an electrical or magnetic field., J. and Berry, R.:A New Method to Control Iridescence Colour in Solid Films of Nanocrystalline Cellulose, Biomacromolecules 12: 167-172 (2011)

NCC in a fluid medium can be oriented in an electrical or magnetic field.
NCC has high strength and stiffness and can amplify these properties to a matrix in which it is properly embedded.
NCC can impart impact and abrasion resistance to materials


Share RecommendKeepReplyMark as Last Read

To: donpat who wrote (36)12/24/2011 1:01:21 PM
From: donpat
   of 176
A New Sensor To Detect Lung Cancer From Exhaled Breath

Article Date: 24 Dec 2011 - 0:00 PST

Tecnalia, through the Interreg project Medisen, is contributing to develop biosensors capable of detecting the presence of tumour markers of lung cancerin exhaled breath. This is possible because of the changes produced within the organism of an ill person, changes reflected in the exhaled breath of the patient and which enable determining the presence of this type of marker during the initial stages of the disease.

Some illnesses such as lung and stomach cancer or liver diseases which, due to the difficulty of diagnosis, have symptoms that are often confused with routine disorders. Therefore, in most cases, the disease is only detected at an advanced stage. New methods for early detection are being investigated as an urgent need.

Patients with lung cancer, treated in the Section of Medical Oncology of the Institute of Onco-Haemathology of the Donostia Hospital (IDOH) have collaborated in this phase of the project. For that, the Ethic Committee of the Clinical Research of Euskadi (CEIC) gave the authorization to the Instituto Biodonostia for the clinical trials.

Human breath, whether from a healthy or ill person, is comprised of a hundreds of organic compounds: acetone, methanol, butanol, hydrocarbons, amongst others. There is not a single specific component in the exhaled breath capable of acting as a marker for the diagnosis of lung cancer. A range of biomarkers and its combination should be selected. The compounds of interest are generally to be found at 1-20 parts per billion (ppb) in healthy human breath but can be increased 10-100-fold in the breath of sick patients. In order to be able to detect these changes the development of novel materials was required.

During the first phase of the project, breath samples were collected by the hospital staff by a breath collecting device. A detailed analysis of the most representative compounds present in the breath samples has been carried out and the family or families of compounds required to act as markers for the presence of lung cancer selected. Organic compounds have been analysed using gas chromatograph/mass spectrometry analysis (GC/MS). Then, the GC/MS results of breath tests have been analysed by statistical and structural algorithms to discriminate and identify "healthy and "cancerous" patterns that really provide information for the design of the sensor.

In parallel, novel materials for the detection of the selected organic compounds have been developed by Tecnalia in order to increase the sensitivity of the devices. Participating together with Tecnalia in this project were the Instituto de Tecnologías Químicas Emergentes de La Rioja (Inter-Química) designing the sensor device and the University of Perpignan (France) testing the novel materials.

As a conclusion, the biosensors will facilitate the diagnosis of certain diseases; mainly those located in the lungs, at the initial stages of the illness, which could increase considerably the chances of survival.

Share RecommendKeepReplyMark as Last Read

From: donpat1/16/2012 9:57:28 PM
   of 176
OLED - Samsung - CNT - University of California - Apple

Samsung looks to borrow $1 billion to expand production capacity in Austin, Texas

By Darren Murph posted Jan 16th 2012 8:24PM

When you're producing chips for the iPad and iPhone, you need a serious facility to meet those demands. And evidently, Samsung's not foreseeing its legal battles with Apple to cause any wrinkles in said plans. In fact, Bloomberg is reporting that Sammy has "sent requests for proposals to banks to borrow as much as $1 billion to expand production capacity at its factory in Austin, Texas," with the bonds to be issued by Samsung's US unit. It's bruited that the company -- which has around $19.2 billion in cash -- may sell its first overseas bonds since 1997 due to the impossibly low cost of borrowing money these days, and in a time where positive economic news is tough to come by, it's quite the relief to see a bit of forward progress come from historically low interest rates. Reuters is reporting that the investment will mostly be used to "boost production of mobile chips and next-generation OLED (organic light-emitting diode) display panels," but specific details beyond that remain murky.

Here's the future - lighting AND TV - and remember - CNTs emitting electrons = KEESMANN (and RAMAN!):



Suspension-deposited carbon-nanotube networks for flexible active-matrix displays

Share RecommendKeepReplyMark as Last Read
Previous 10 Next 10 

Copyright © 1995-2018 Knight Sac Media. All rights reserved.Stock quotes are delayed at least 15 minutes - See Terms of Use.